Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mast Cell Disorders
•
Primary Care
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Related Questions
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
Do you switch from 0.15 mg to 0.3 mg epinephrine at 55lbs or 66lbs?
Do you continue shots when a patient transfers under your care and has been receiving less than effective doses of AIT, but insist they have been effective?
Would you ever use dupilumab for atopic dermatitis in a patient who also has EGPA?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
What are the implications of checking post-vaccine titers after administration of Prevnar 20 compared to PPSV23?
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell activation syndrome besides omalizumab?
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
When do you consider extending the dosing interval for patients on biologics with CRSwNP?
